Skip to main content
HARBIN GLORIA PHARMACEUTICALS Co., LTD logo

HARBIN GLORIA PHARMACEUTICALS Co., LTD — Investor Relations & Filings

Ticker · 002437 ISIN · CNE100000QG8 LEI · 300300K1ZDAXM6M73U33 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,133 across all filing types
Latest filing 2026-05-18 Declaration of Voting R…
Country CN China
Listing Shenzhen Stock Exchange 002437

About HARBIN GLORIA PHARMACEUTICALS Co., LTD

https://www.gloria.cc

Harbin Gloria Pharmaceuticals Co., Ltd. focuses on the research, development, manufacturing, and commercialization of diverse pharmaceutical products. The company specializes in therapeutic areas including cardiovascular and cerebrovascular diseases, orthopedics, oncology, and metabolic disorders. Its portfolio comprises chemical drugs, biological products, and specialized injections, with key products such as Alprostadil and Deer Melon Polypeptide. The organization prioritizes technological innovation through a dedicated R&D infrastructure aimed at developing both generic and innovative medications. It maintains multiple production facilities and an extensive distribution network to supply healthcare solutions for chronic and acute conditions.

Recent filings

Filing Released Lang Actions
2025年年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 90% confidence The document is an official announcement of the 2025 Annual General Meeting resolutions (‘年度股东会决议公告’) for Harbin YuHeng Pharma Co., detailing attendance and vote counts/percentages for each proposal. It is not the full meeting materials or an investor presentation but specifically reports the voting results. This fits the “Declaration of Voting Results & Voting Rights Announcements” category.
2026-05-18 Chinese
2025年年度股东会法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 85% confidence The document is a legal opinion letter by a law firm on the legality of the 2025 annual shareholders’ meeting, but its core content includes the official vote counts and percentages for each of the eight proposals. This aligns with “Declaration of Voting Results & Voting Rights Announcements (DVA)” – which covers publication of the formal voting results at a general meeting. Thus, it should be classified as DVA.
2026-05-18 Chinese
关于2024年限制性股票激励计划首次授予部分第二个限售期解除限售股份上市流通的提示性公告
Share Issue/Capital Change Classification · 95% confidence The document is a detailed announcement from Harbin Yuheng Pharmaceutical Co., Ltd. regarding the unlocking and listing of restricted shares under its 2024 restricted stock incentive plan. It includes extensive information about the approval process, conditions for unlocking shares, the number of shares and participants involved, and the impact on share capital structure. The document is not a financial report, earnings release, or management discussion but rather a formal disclosure about stock incentive plan share unlock and listing. It is not a proxy solicitation or voting results announcement, nor a board or management change notice. The content fits best with announcements related to share capital changes specifically about restricted stock unlocking and listing. Therefore, the most appropriate classification is Share Issue/Capital Change (SHA). The document length and detail confirm it is not a brief announcement or a report publication notice, but a substantive disclosure about capital changes due to stock incentive plan unlocking.
2026-05-08 Chinese
2026年一季度业绩预增公告
Earnings Release Classification · 90% confidence The document is a Chinese “2026年一季度业绩预增公告,” providing a preliminary profit forecast for Q1 2026 (projected net profit range, year‐over‐year growth, EPS guidance). It is a short announcement of key financial highlights and guidance rather than a full interim report or audited results, matching the definition of an Earnings Release (initial announcement of quarterly/periodical financial results). Q1 2026
2026-04-14 Chinese
关于回购并注销离职人员已获授但尚未解除限售的限制性股票的公告
Transaction in Own Shares Classification · 95% confidence The document is a detailed announcement from Harbin Yuheng Pharmaceutical Co., Ltd. regarding the repurchase and cancellation of restricted shares granted to former employees who have left the company. It includes specifics about board meetings, shareholder approvals, legal opinions, share quantities, prices, and the impact on share capital structure. The content focuses on a corporate action related to share repurchase and cancellation, with no financial statements or earnings data presented. The document is not a full financial report, earnings release, or management discussion but rather a formal announcement of a capital change event involving share repurchase and cancellation. Therefore, the appropriate classification is 'Transaction in Own Shares' (POS). The document length and detail confirm it is not a brief announcement but a substantive disclosure of the transaction.
2025-12-29 Chinese
2024年限制性股票激励计划之回购注销部分限制性股票事项的法律意见书
Regulatory Filings Classification · 72% confidence The document is a legal opinion letter issued by Beijing Zhide Law Firm regarding the repurchase and cancellation of restricted stock under the company’s 2024 equity incentive plan. It is not a financial report (10-K, IR, ER, etc.), nor an earnings call transcript, nor a management or M&A filing. It is an external legal compliance document that the company may publicly disclose as part of its regulatory filings. It does not itself announce share issuances, dividends, or management changes but provides legal opinions on share repurchase compliance. Therefore it falls into the fallback category for miscellaneous regulatory compliance filings: Regulatory Filings (RNS).
2025-12-29 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.